查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
靜脈疾病治療的全球市場 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)
市場調查報告書
商品編碼
1121709

靜脈疾病治療的全球市場 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)

Venous Diseases Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球靜脈疾病治療市場相關調查分析，市場趨勢，市場區隔分析，地區分析，企業簡介等資訊。

目錄

第1章 序文

第2章 前提條件與調查手法

第3章 摘要整理:全球靜脈疾病治療市場

第4章 市場概要

  • 簡介
    • 市場區隔定義
    • 產業的演進/發展
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 波特的五力分析

第5章 主要洞察

  • 各地區/全球法規情境
  • 技術進步
  • 開發平台分析
  • 主要的合併和收購
  • 全球主要國家的疾病的盛行率與發病率
  • 各地區/全球償付情境

第6章 全球靜脈疾病治療的分析與預測:各治療類型

  • 簡介和定義
  • 主要的調查結果/發展
  • 市場價值預測(2017年～2031年):各治療類型
    • 手術
    • 治療
  • 市場魅力分析:各治療類型

第7章 全球靜脈疾病治療的分析與預測:各疾病類型

  • 簡介和定義
  • 主要的調查結果/發展
  • 市場價值預測(2017年～2031年):各疾病類型
    • 深層靜脈栓塞症性靜脈炎
    • 靜脈瘤
    • 表在性血栓性靜脈炎
    • 慢性靜脈功能不全
    • 靜脈潰瘍
    • 其他
  • 市場魅力分析:各疾病類型

第8章 全球靜脈疾病治療的分析與預測:各產品類型

  • 簡介和定義
  • 主要的調查結果/發展
  • 市場價值預測(2017年～2031年):各產品類型
    • 切除設備
    • 靜脈支架
    • 靜脈封閉治療
    • 硬化療法注射
    • 其他
  • 市場魅力分析:各產品類型

第9章 全球靜脈疾病治療的分析與預測:各終端用戶

  • 簡介和定義
  • 主要的調查結果/發展
  • 市場價值預測(2017年～2031年):各終端用戶
    • 醫院
    • 診療所
    • 門診中心
  • 市場魅力分析:各終端用戶

第10章 全球靜脈疾病治療的分析與預測:各地區

  • 主要的調查結果
  • 市場價值預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 市場魅力分析:各地區

第11章 北美的靜脈疾病治療的分析與預測

  • 簡介
    • 主要的調查結果
  • 市場價值預測(2017年～2031年):各治療類型
    • 手術
    • 治療
  • 市場價值預測(2017年～2031年):各疾病類型
    • 深層靜脈栓塞症性靜脈炎
    • 靜脈瘤
    • 表在性血栓性靜脈炎
    • 慢性靜脈功能不全
    • 靜脈潰瘍
    • 其他
  • 市場價值預測(2017年～2031年):各產品類型
    • 切除設備
    • 靜脈支架
    • 靜脈封閉治療
    • 硬化療法注射
    • 其他
  • 市場價值預測(2017年～2031年):各終端用戶
    • 醫院
    • 診療所
    • 門診中心
  • 市場價值預測(2017年～2031年):各國/各地區
    • 美國
    • 加拿大
  • 市場魅力分析
    • 各治療類型
    • 各疾病類型
    • 各產品類型
    • 各終端用戶
    • 各國/各地區

第12章 歐洲的靜脈疾病治療的分析與預測

第13章 亞太地區的靜脈疾病治療的分析與預測

第14章 南美的靜脈疾病治療的分析與預測

第15章 中東、非洲的靜脈疾病治療的分析與預測

第16章 競爭情形

  • 市場企業 - 競爭矩陣(階層、各企業規模)
  • 市場佔有率分析(2021年):各企業
  • 企業簡介
    • Zimmer Biomet Holdings, Inc.
    • Medtronic
    • AngioDynamics
    • Alma Lasers
    • Biolitec AG Untere Viaduktgasse
    • Becton, Dickinson and Company
    • Boston Scientific Corporation
    • Abbott Laboratories
    • B. Braun Melsungen AG
    • Teleflex Incorporated
    • Lumenis
    • Philips
Product Code: TMRGL84870

The report provides revenue of the global venous diseases treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global venous diseases treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the venous diseases treatment market.

The report delves into the competitive landscape of the global venous diseases treatment market. Key players operating in the global venous diseases treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global venous diseases treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Venous Diseases Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Porter's Five Force Analysis

5. Key Insights

  • 5.1. Regulatory Scenario by Region/globally
  • 5.2. Technological Advancements
  • 5.3. Pipeline Analysis
  • 5.4. Key Mergers & Acquisitions
  • 5.5. Disease Prevalence & Incidence Rate globally with key countries
  • 5.6. Reimbursement Scenario by Region/globally

6. Global Venous Diseases Treatment Analysis and Forecast, by Treatment Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Treatment, 2017-2031
    • 6.3.1. Surgeries
      • 6.3.1.1. Angioplasty or Stenting
      • 6.3.1.2. Vein Ligation and Stripping
      • 6.3.1.3. Vena Cava Filter
      • 6.3.1.4. Ambulatory Phlebectomy
      • 6.3.1.5. Others
    • 6.3.2. Therapies
      • 6.3.2.1. Sclerotherapy
      • 6.3.2.2. Radiofrequency Ablation Therapy
      • 6.3.2.3. Laser Treatment
  • 6.4. Market Attractiveness Analysis, by Treatment

7. Global Venous Diseases Treatment Analysis and Forecast, by Disease Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Disease Type, 2017-2031
    • 7.3.1. Deep-vein Thrombophlebitis
    • 7.3.2. Varicose Veins
    • 7.3.3. Superficial Thrombophlebitis
    • 7.3.4. Chronic Venous Insufficiency
    • 7.3.5. Venous Ulcers
    • 7.3.6. Others
  • 7.4. Market Attractiveness Analysis, by Disease Type

8. Global Venous Diseases Treatment Analysis and Forecast, by Product Type

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Product Type, 2017-2031
    • 8.3.1. Ablation Devices
    • 8.3.2. Venous Stents
    • 8.3.3. Venous Closure Treatments
    • 8.3.4. Sclerotherapy Injection
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis, by Product Type

9. Global Venous Diseases Treatment Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Hospitals
    • 9.3.2. Clinics
    • 9.3.3. Ambulatory centers
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Venous Diseases Treatment Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Venous Diseases Treatment Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment, 2017-2031
    • 11.2.1. Surgeries
      • 11.2.1.1. Angioplasty or Stenting
      • 11.2.1.2. Vein Ligation and Stripping
      • 11.2.1.3. Vena Cava Filter
      • 11.2.1.4. Ambulatory Phlebectomy
      • 11.2.1.5. Others
    • 11.2.2. Therapies
      • 11.2.2.1. Sclerotherapy
      • 11.2.2.2. Radiofrequency Ablation Therapy
      • 11.2.2.3. Laser Treatment
  • 11.3. Market Value Forecast, by Disease Type, 2017-2031
    • 11.3.1. Deep-vein Thrombophlebitis
    • 11.3.2. Varicose Veins
    • 11.3.3. Superficial Thrombophlebitis
    • 11.3.4. Chronic Venous Insufficiency
    • 11.3.5. Venous Ulcers
    • 11.3.6. Others
  • 11.4. Market Value Forecast, by Product Type, 2017-2031
    • 11.4.1. Ablation Devices
    • 11.4.2. Venous Stents
    • 11.4.3. Venous Closure Treatments
    • 11.4.4. Sclerotherapy Injection
    • 11.4.5. Others
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. Hospitals
    • 11.5.2. Clinics
    • 11.5.3. Ambulatory centers
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Treatment
    • 11.7.2. By Disease Type
    • 11.7.3. By Product Type
    • 11.7.4. By End-user
    • 11.7.5. By Country/Sub-region

12. Europe Venous Diseases Treatment Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment, 2017-2031
    • 12.2.1. Surgeries
      • 12.2.1.1. Angioplasty or Stenting
      • 12.2.1.2. Vein Ligation and Stripping
      • 12.2.1.3. VeEnd Use Cava Filter
      • 12.2.1.4. Ambulatory Phlebectomy
      • 12.2.1.5. Others
    • 12.2.2. Therapies
      • 12.2.2.1. Sclerotherapy
      • 12.2.2.2. Radiofrequency Ablation Therapy
      • 12.2.2.3. Laser Treatment
  • 12.3. Market Value Forecast, by Disease Type, 2017-2031
    • 12.3.1. Deep-vein Thrombophlebitis
    • 12.3.2. Varicose Veins
    • 12.3.3. Superficial Thrombophlebitis
    • 12.3.4. Chronic Venous Insufficiency
    • 12.3.5. Venous Ulcers
    • 12.3.6. Others
  • 12.4. Market Value Forecast, by Product Type, 2017-2031
    • 12.4.1. Ablation Devices
    • 12.4.2. Venous Stents
    • 12.4.3. Venous Closure Treatments
    • 12.4.4. Sclerotherapy Injection
    • 12.4.5. Others
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. Hospitals
    • 12.5.2. Clinics
    • 12.5.3. Ambulatory centers
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Treatment
    • 12.7.2. By Disease Type
    • 12.7.3. By Product Type
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Venous Diseases Treatment Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment, 2017-2031
    • 13.2.1. Surgeries
      • 13.2.1.1. Angioplasty or Stenting
      • 13.2.1.2. Vein Ligation and Stripping
      • 13.2.1.3. VeEnd Use Cava Filter
      • 13.2.1.4. Ambulatory Phlebectomy
      • 13.2.1.5. Others
    • 13.2.2. Therapies
      • 13.2.2.1. Sclerotherapy
      • 13.2.2.2. Radiofrequency Ablation Therapy
      • 13.2.2.3. Laser Treatment
  • 13.3. Market Value Forecast, by Disease Type, 2017-2031
    • 13.3.1. Deep-vein Thrombophlebitis
    • 13.3.2. Varicose Veins
    • 13.3.3. Superficial Thrombophlebitis
    • 13.3.4. Chronic Venous Insufficiency
    • 13.3.5. Venous Ulcers
    • 13.3.6. Others
  • 13.4. Market Value Forecast, by Product Type, 2017-2031
    • 13.4.1. Ablation Devices
    • 13.4.2. Venous Stents
    • 13.4.3. Venous Closure Treatments
    • 13.4.4. Sclerotherapy Injection
    • 13.4.5. Others
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. Hospitals
    • 13.5.2. Clinics
    • 13.5.3. Ambulatory centers
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Treatment
    • 13.7.2. By Disease Type
    • 13.7.3. By Product Type
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Venous Diseases Treatment Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Treatment, 2017-2031
    • 14.2.1. Surgeries
      • 14.2.1.1. Angioplasty or Stenting
      • 14.2.1.2. Vein Ligation and Stripping
      • 14.2.1.3. VeEnd Use Cava Filter
      • 14.2.1.4. Ambulatory Phlebectomy
      • 14.2.1.5. Others
    • 14.2.2. Therapies
      • 14.2.2.1. Sclerotherapy
      • 14.2.2.2. Radiofrequency Ablation Therapy
      • 14.2.2.3. Laser Treatment
  • 14.3. Market Value Forecast, by Disease Type, 2017-2031
    • 14.3.1. Deep-vein Thrombophlebitis
    • 14.3.2. Varicose Veins
    • 14.3.3. Superficial Thrombophlebitis
    • 14.3.4. Chronic Venous Insufficiency
    • 14.3.5. Venous Ulcers
    • 14.3.6. Others
  • 14.4. Market Value Forecast, by Product Type, 2017-2031
    • 14.4.1. Ablation Devices
    • 14.4.2. Venous Stents
    • 14.4.3. Venous Closure Treatments
    • 14.4.4. Sclerotherapy Injection
    • 14.4.5. Others
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. Hospitals
    • 14.5.2. Clinics
    • 14.5.3. Ambulatory centers
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Treatment
    • 14.7.2. By Disease Type
    • 14.7.3. By Product Type
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Venous Diseases Treatment Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Treatment, 2017-2031
    • 15.2.1. Surgeries
      • 15.2.1.1. Angioplasty or Stenting
      • 15.2.1.2. Vein Ligation and Stripping
      • 15.2.1.3. VeEnd Use Cava Filter
      • 15.2.1.4. Ambulatory Phlebectomy
      • 15.2.1.5. Others
    • 15.2.2. Therapies
      • 15.2.2.1. Sclerotherapy
      • 15.2.2.2. Radiofrequency Ablation Therapy
      • 15.2.2.3. Laser Treatment
  • 15.3. Market Value Forecast, by Disease Type, 2017-2031
    • 15.3.1. Deep-vein Thrombophlebitis
    • 15.3.2. Varicose Veins
    • 15.3.3. Superficial Thrombophlebitis
    • 15.3.4. Chronic Venous Insufficiency
    • 15.3.5. Venous Ulcers
    • 15.3.6. Others
  • 15.4. Market Value Forecast, by Product Type, 2017-2031
    • 15.4.1. Ablation Devices
    • 15.4.2. Venous Stents
    • 15.4.3. Venous Closure Treatments
    • 15.4.4. Sclerotherapy Injection
    • 15.4.5. Others
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. Hospitals
    • 15.5.2. Clinics
    • 15.5.3. Ambulatory centers
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031

16. Competitive Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company, 2021
  • 16.3. Company Profiles
    • 16.3.1. Zimmer Biomet Holdings, Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Company Financials
      • 16.3.1.3. Growth Strategies
      • 16.3.1.4. SWOT Analysis
    • 16.3.2. Medtronic
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Company Financials
      • 16.3.2.3. Growth Strategies
      • 16.3.2.4. SWOT Analysis
    • 16.3.3. AngioDynamics
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Company Financials
      • 16.3.3.3. Growth Strategies
      • 16.3.3.4. SWOT Analysis
    • 16.3.4. Alma Lasers
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Company Financials
      • 16.3.4.3. Growth Strategies
      • 16.3.4.4. SWOT Analysis
    • 16.3.5. Biolitec AG Untere Viaduktgasse
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Company Financials
      • 16.3.5.3. Growth Strategies
      • 16.3.5.4. SWOT Analysis
    • 16.3.6. Becton, Dickinson and Company
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Company Financials
      • 16.3.6.3. Growth Strategies
      • 16.3.6.4. SWOT Analysis
    • 16.3.7. Boston Scientific Corporation
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Company Financials
      • 16.3.7.3. Growth Strategies
      • 16.3.7.4. SWOT Analysis
    • 16.3.8. Abbott Laboratories
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Company Financials
      • 16.3.8.3. Growth Strategies
      • 16.3.8.4. SWOT Analysis
    • 16.3.9. B. Braun Melsungen AG
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Company Financials
      • 16.3.9.3. Growth Strategies
      • 16.3.9.4. SWOT Analysis
    • 16.3.10. Teleflex Incorporated
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Company Financials
      • 16.3.10.3. Growth Strategies
      • 16.3.10.4. SWOT Analysis
    • 16.3.11. Lumenis
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Company Financials
      • 16.3.11.3. Growth Strategies
      • 16.3.11.4. SWOT Analysis
    • 16.3.12. Philips
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Company Financials
      • 16.3.12.3. Growth Strategies
      • 16.3.12.4. SWOT Analysis

List of Tables

  • Table 01: Global Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 02: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
  • Table 03: Global Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
  • Table 04: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
  • Table 05: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Region, 2017-2031
  • Table 06: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by Country, 2017-2031
  • Table 07: North America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 08: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
  • Table 09: North America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
  • Table 10: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
  • Table 11: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 13: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
  • Table 14: Europe Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
  • Table 15: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
  • Table 16: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 18: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
  • Table 19: Asia Pacific Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
  • Table 20: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
  • Table 21: India Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 22: India Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
  • Table 23: India Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
  • Table 24: India Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
  • Table 25: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 26: Latin America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 27: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
  • Table 28: Latin America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
  • Table 29: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
  • Table 30: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 31: Middle East & Africa Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 32: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
  • Table 33: Middle East & Africa Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
  • Table 34: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031

List of Figures

  • Figure 01: Global Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
  • Figure 02: Global Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
  • Figure 03: Global Venous Diseases Treatment Revenue (US$ Bn), by Surgeries, 2017-2031
  • Figure 04: Global Venous Diseases Treatment Revenue (US$ Bn), by Therapies, 2017-2031
  • Figure 05: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
  • Figure 06: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Product Type, 2017-2031
  • Figure 07: Global Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
  • Figure 08: Global Venous Diseases Treatment Attractiveness Analysis, by Angioplasty or Stenting, 2022-2031
  • Figure 09: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Vein Ligation and stripping, 2017-2031
  • Figure 10: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Vena Cava Filter, 2017-2031
  • Figure 11: Global Venous Diseases Treatment Value Share Analysis, by Ambulatory Phlebectomy Type, 2021 and 2031
  • Figure 12: Global Venous Diseases Treatment Attractiveness Analysis, by Others, 2022-2031
  • Figure 13: Global Venous Diseases Treatment Revenue (US$ Bn), by Sclerotherapy, 2017-2031
  • Figure 14: Global Venous Diseases Treatment Revenue (US$ Bn), by Laser treatment, 2017-2031
  • Figure 15: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Radiofrequency ablation therapy, 2017-2031
  • Figure 16: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Varicose Veins 2017-2031
  • Figure 17: Global Venous Diseases Treatment Value Share Analysis, by Superficial Thrombophlebitis, 2021 and 2031
  • Figure 18: Global Venous Diseases Treatment Attractiveness Analysis, by Deep-vein Thrombophlebitis, 2022-2031
  • Figure 19: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Chronic Venous Insufficiency, 2017-2031
  • Figure 20: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Venous ulcers, 2017-2031
  • Figure 21: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Others, 2017-2031
  • Figure 22: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Ablation Devices, 2017-2031
  • Figure 23: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Sclerotherapy Injection, 2017-2031
  • Figure 24: Global Venous Diseases Treatment Attractiveness Analysis, by Venous Closure Treatments, 2022-2031
  • Figure 25: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Venous stents
  • Figure 26: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Others, 2017-2031
  • Figure 27: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Hospitals, 2017-2031
  • Figure 28: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Clinics, 2017-2031
  • Figure 29: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Ambulatory centers, 2017-2031
  • Figure 30: Global Venous Diseases Treatment Value Share Analysis, by Region, 2021 and 2031
  • Figure 31: Global Venous Diseases Treatment Attractiveness Analysis, by Region, 2022-2031
  • Figure 32: North America Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
  • Figure 33: North America Venous Diseases Treatment Value Share Analysis, by Country, 2021 and 2031
  • Figure 34: North America Venous Diseases Treatment Attractiveness Analysis, by Country, 2022-2031
  • Figure 35: North America Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
  • Figure 36: North America Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
  • Figure 37: North America Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
  • Figure 38: North America Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 39: North America Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
  • Figure 40: North America Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
  • Figure 41: North America Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
  • Figure 36: North America Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
  • Figure 37: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
  • Figure 38: Europe Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 39: Europe Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 40: Europe Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
  • Figure 41: Europe Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
  • Figure 42: Europe Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
  • Figure 43: Europe Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 44: Europe Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
  • Figure 45: Europe Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
  • Figure 46: Europe Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
  • Figure 47: Europe Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
  • Figure 48: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
  • Figure 49: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 50: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 51: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
  • Figure 52: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
  • Figure 53: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
  • Figure 54: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 55: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
  • Figure 56: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
  • Figure 57: Asia Pacific Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
  • Figure 58: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
  • Figure 59: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
  • Figure 60: Latin America Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 61: Latin America Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 62: Latin America Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
  • Figure 63: Latin America Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
  • Figure 64: Latin America Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
  • Figure 65: Latin America Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 66: Latin America Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
  • Figure 67: Latin America Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
  • Figure 68: Latin America Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
  • Figure 69: Latin America Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
  • Figure 70: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
  • Figure 71: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 72: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 73: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
  • Figure 74: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
  • Figure 75: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
  • Figure 76: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 77: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
  • Figure 78: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
  • Figure 79: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
  • Figure 80: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
  • Figure 81: Company Market Share Analysis, 2021